Table 2.
Pediatric patient demographics, laboratory values, and clinical course.
| Variables | All (N = 22) | COVID-19(N = 7) | MIS-C(N = 9) | Kawasaki(N = 3) | Fevera(N = 3) | P valueb |
|---|---|---|---|---|---|---|
| Age, years, mean ± SD | 9.9 ± 5.9 | 15.6 ± 5.8 | 8.8 ± 3.3 | 4.3 ± 3.2 | 5.7 ± 4.7 | 0.004 |
| Gender: male, N (%) | 13 (59%) | 3 (43%) | 5 (56%) | 2 (67%) | 3 (100%) | 0.398 |
| LOS (days), mean ± SD | 14.0 ± 17.1 | 24.3 ± 27.2 | 12.0 ± 6.7 | 5.7 ± 2.1 | 4.0 ± 1.0 | 0.225 |
| PICU: yes, N (%) | 14 (64%) | 4 (57%) | 9 (100%) | 1 (33%) | 0 (0%) | 0.008 |
| Laboratory valuesc | ||||||
| PCR+, N (%) | 9 (41%) | 7 (100%) | 2 (22%) | 0 (0%) | 0 (0%) | 0.001 |
| IgG+, N (%) | 9/14 (64%) | 1 (50%) | 8 (89%) | 0 (0%) | 0 (0%) | 0.008 |
| WBCd ×103 (cells/µL) | 24.2 ± 42.2 | 59.1 ± 70.6 | 9.3 ± 4.7 | 14.7 ± 2.2 | 8.5 ± 6.3 | 0.004 |
| CRP (µg/mL) | 14.5 ± 8.7 | 12.0 ± 13.0 | 15.7 ± 7.9 | 19.3 ± 1.4 | 8.8 ± 2.3 | 0.448 |
| D-dimers (ng/mL) | 2401 ± 1679 | 1530 ± 530 | 3056 ± 1793 | 2792 ± 0 | 563 ± 393 | 0.204 |
| sPLA2 (ng/mL) | 190 ± 306 | 155 ± 172 | 301 ± 459 | 49 ± 67 | 33 ± 22 | 0.506 |
CRP: C-reactive protein; IgG: Immunoglobulin G; LOS: length of stay; MIS-C: multisystem inflammatory syndrome in children; PCR: polymerase chain reaction; PICU: pediatric intensive care unit; sPLA2: secretory phospholipase 2; WBC: white blood cell.
aExcluded febrile patients with Epstein-Barr virus/hemophagocytic lymphohistiocytosis and Brucellosis.
bOne-way ANOVA for continuous variables or Chi-square test for categorical variables, alpha = 0.05. Data are represented as mean ± SD for continuous data or N (%) for nominal data.
cDenominators represent the number of patients in each group for whom testing was performed.
dTwo patients with COVID-19 had new diagnoses acute myelogenous leukemia (AML) and highly elevated WBC.